摘要
目的:研究米氮平与氟西汀治疗抑郁症的疗效和安全性。方法:将70例抑郁症患者随机分成两组,分别予以米氮平和氟西汀治疗8周,采用汉密尔顿抑郁量表(HAMD)和不良反应量表(TESS)在治疗前及治疗1、2、4、8周末分别评定疗效与不良反应。结果:两组在治疗前及治疗1、2、4、8周末经HAMD评分比较,第1周末米氮平组减分率大于氟西汀组,有显著性差异(P<0.05),第2周末氟西汀组减分率大于米氮平组,有显著性差异(P<0.05),治疗4、8周两组间疗效无统计学意义(P>0.05),两组不良反应比较无显著性差异。结论:米氮平与氟西汀治疗抑郁症疗效相当,米氮平起效较快,建议临床推广应用。
Objective：To explore the efficacy and safety of Mirtazapine and Fluoxetine in the treatment of depression. Methods：70 patients with depression were randomly devided into two groups ,with Mirtazapine or Fluoxetine for 8 weeks. HAMD scale and Tess scale were used to evaluate effi- cacy and side effects respectively before and at ends of 1,2,4,8 weeks of treatment. Results： Compare two groups＇ HAMD scores before treatment and after treatment of 1,2,4,8 weeks. At the 1 st weekend, the reduction of mirtazapine group was greater than fluoxetine group. There was significant different（ P 〈 0. 05 ）. At the 2nd weekend, the reduction rate of fluoxetine group was greater than mirtazapine group. There was significant different （ P 〈 0.05 ）. After treatment of 4,8 weeks, there was no statistical different in efficacy （P 〉 0.05 ）. Two groups showed no significant difference in adverse reactionsl Conclusion： In the treatment of depression, Mirtazapine and Fluoxetine are similar in efficacy. Mirtazapine is quicker in efficacy beginning and it can be used in clinical practice.
出处
《中国民康医学》
2011年第18期2233-2234,共2页
Medical Journal of Chinese People’s Health
关键词
米氮平
氟西汀
抑郁症
Mirtazapine
Fluoxetine
depression
